Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Impaired gastric emptying07.02.02.0040.002343%
Incoherent17.02.08.002; 19.10.03.0060.000703%Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal ischaemia24.04.08.001; 07.15.02.0010.000244%Not Available
Intestinal obstruction07.13.01.0020.004686%Not Available
Intestinal perforation07.04.06.0020.000703%Not Available
Intracranial pressure increased17.07.02.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Ischaemic hepatitis09.01.07.018; 24.04.07.0040.000244%Not Available
Joint swelling15.01.02.004--Not Available
Lacrimation increased06.08.02.004--
Large intestine perforation12.02.03.005; 07.04.06.0050.000795%
Laryngospasm22.04.02.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.009138%
Leukoencephalopathy17.13.02.0030.004217%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lip swelling10.01.05.005; 07.05.04.005; 23.04.01.007--Not Available
Lipase increased13.05.01.0030.000937%
Livedo reticularis24.03.04.003; 23.06.05.0010.001171%Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.0040.014292%Not Available
Lung disorder22.02.07.001--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 21 Pages